"These activities are related to the active pharmaceutical ingredient and finished drug product for an oral formulation of a recombinantly produced investigational parathyroid hormone PTH analog for the treatment of osteoporosis in postmenopausal women in advance of GSK's potential decision to study the molecule in a Phase 3 program."